protein expression or hemichannel closure in the heart and lung tissue of SCI animals. The expression levels of other major connexin proteins including Connexin30 in astrocytes, Connexin36 in neurons and Connexin47 in oligodendrocytes were also unaltered by systemic delivery of Peptide5 in either the injured or non-injured spinal cords. In addition, systemic delivery of Peptide5 had no significant effect on the plasma levels of cytokines, chemokines or growth factors. These data indicate that the systemic delivery of Peptide5 is unlikely to cause any off-target or adverse effects and may thus be a safe treatment option for traumatic SCI.
Introduction
Peptide5 is a synthetic peptide that mimics a sequence in the extracellular loop 2 of Connexin43, a ubiquitously expressed gap junction protein found in the spinal cord (Lee et al. 2005; Stehberg et al. 2012; Theriault et al. 1997) . Under pathological conditions, Connexin43 channel-mediated communication is involved in secondary cell death by propagating neurotoxic molecules, such as glutamate, nitric oxide, lactate, arachidonate, ammonia, reactive oxygen species and calcium waves from injured cells to adjacent healthy cells, a process known as the bystander effect (Lin et al. 1998; Scemes et al. 2000; Theriault et al. 1997) . Additionally, the opening of uncoupled gap junction hemichannels alters the permeability of cell membranes to release neurotoxins to the extracellular space and can trigger calcium waves, which are then received by surrounding, previously uninjured cells Abstract Systemic administration of a Connexin43 mimetic peptide, Peptide5, has been shown to reduce secondary tissue damage and improve functional recovery after spinal cord injury (SCI). This study investigated safety measures and potential off-target effects of Peptide5 systemic administration. Rats were subjected to a mild contusion SCI using the New York University impactor. One cohort was injected intraperitoneally with a single dose of fluorescently labelled Peptide5 and euthanised at 2 or 4 h post-injury for peptide distribution analysis. A second cohort received intraperitoneal injections of Peptide5 or a scrambled peptide and was culled at 8 or 24 h postinjury for the analysis of connexin proteins and systemic cytokine profile. We found that Peptide5 did not cross the blood-spinal cord barrier in control animals, but reached the lesion area in the spinal cord-injured animals without entering non-injured tissue. There was no evidence that the systemic administration of Peptide5 modulates Connexin43 (Davidson et al. 2015; Decrock et al. 2015; Orellana et al. 2011 ; Thompson et al. 2006; Ye et al. 2003) . Peptide5 is able to regulate the communication of Connexin43 gap junctions and hemichannels independently, with short incubation times or low concentration restricting hemichannel opening without affecting the communication of existing gap junctions, whereas long incubation times or high concentration have been reported to prevent gap junction and hemichannel communication in experimental preclinical models (Abudara et al. 2014; Leybaert et al. 2003; O'Carroll et al. 2008; Yoon et al. 2010) . Although the exact mechanisms of Peptide5 action remain to be fully elucidated, the most recent study revealed that Peptide5 acts on the extracellular loop 2 of Connexin43 (Kim et al. 2017) . The authors also demonstrated that the Peptide5 sequence provides the most effective Connexin43 hemichannel blocking, with the SRPTEKT motif being central to the Peptide5 mechanism (Kim et al. 2017) .
Using an intrathecal catheter and an osmotic pump to deliver Peptide5 directly to the lesion area of the spinal cord in a rat contusion model, early studies demonstrated the neuroprotective efficacy of Peptide5 (O'Carroll et al. 2013) . Local application of Peptide5 has also been explored in a number of pathological conditions in the nervous system including retinal ischaemia (Chen et al. 2014 (Chen et al. , 2015 , cerebral ischaemia ( Davidson et al. 2013a ( Davidson et al. , b, 2015 , foetal ischaemia (Davidson et al. 2012a ) and asphyxia (Davidson et al. 2014) . Local administration may not be the most practical option for human spinal patients as, for example, the intrathecal delivery of Peptide5 may normally involve an invasive procedure immediately after a traumatic event, that may not be clinically prudent. Systemic administration is able to deliver proteins and mimetic peptides to the lesion area of the spinal cord even where the capillary bed has been compromised (Han et al. 2010) , thus offering a practical therapeutic approach for people with spinal cord injury (SCI). A study of retinal ischemia-reperfusion with systemic Peptide5 delivery showed significant neuronal protection following peptide treatment (Danesh-Meyer et al. 2012 ) and a recent study by us has shown that systemic Peptide5 delivery is neuroprotective and improves functional recovery in a rat spinal cord contusion model (Mao et al. 2017) . However, the safety profile of Peptide5 after systemic administration has not been experimentally examined.
Connexin43 protein is found in other tissues, including the heart (Gourdie et al. 1993; Gu et al. 2014; Van Kempen et al. 1991 ), brain (Deng et al. 2014; Nakase et al. 2004; Yamamoto et al. 1990 ), testis (Chevallier et al. 2013; Li et al. 2010; Steger et al. 1999) , skin (Chang et al. 2015; Guo et al. 1992; Tada and Hashimoto 1997) and bone marrow (Dorshkind et al. 1993; Dürig et al. 2000; Zhang et al. 2006) . Connexin43 mimetic peptides have been shown to regulate Connexin43 hemichannels and protect against ischaemic injury in the heart (Hawat et al. 2010 (Hawat et al. , 2012 ) and brain (Davidson et al. 2013a (Davidson et al. , b, 2015 . Following our demonstration that systemic delivery of Peptide5 is protective after SCI (Mao et al. 2017) , we sought to assess whether Connexin43 hemichannels and/or gap junctions in tissues such as the heart are affected by this treatment.
In the spinal cord, there is a wide distribution of connexin gap junctions: astrocyte/astrocyte gap junctions contain Connexin30 and 43, neuron/neuron gap junctions contain Connexin36, and oligodendrocyte/astrocyte gap junctions containing Connexin29, 32 and 47, with the major heterotypic gap junction channels being composed of Connexin43-Connexin47 and Connexin30-Connexin32 protein combinations (Kleopa et al. 2004; Lee et al. 2005; Orthmann-Murphy et al. 2008; Rash et al. 1998 Rash et al. , 2001 Tonkin et al. 2015) . Although Connexin43 is the major connexin that has been reported to be altered following traumatic SCI, we also sought to evaluate whether that the expression of other connexins may be changed following blockade of Connexin43 hemichannels by Peptide5 treatment.
In the current study, therefore, as an initial step towards translation to human SCI treatments, we examined safety aspects of Peptide5 systemic administration protocols including tissue distribution and systemic effects in our rat spinal cord injury model.
Materials and methods

Animals and animal care
All experimental protocols and procedures used in the current study were approved by the Animal Care and Ethics Committee of University of Technology Sydney, in accordance with the guidelines of the National Health and Medical Research Council of Australia. There were 57 adult female Sprague-Dawley rats weighing 250-300 g used (Animal Resource Centre, Perth, Australia). All animals were maintained in standard cages with ad-lib water and food on a 12:12 h light-dark cycle. Each animal's weight was checked at least twice a week.
The surgical procedures have been described previously in detail (Mao et al. 2017) . Briefly, rats were anesthetised with 4% isoflurane in 1 L/min oxygen and maintained at 2% isoflurane in 1 L/min oxygen. Local anaesthetic (bupivacaine, 0.5%, 0.02 mL) was injected at the surgical sites before an incision was made through skin and muscle layers over the dorsal midline. A T10 laminectomy was performed to expose the spinal cord and, in the 'SCI' groups (n = 30), animals were subject to a mild contusion injury (6.25 mm drop, 10 g weight) to the T10 spinal cord using the New
3
York University impactor. The 'sham' group (n = 19) were subject to a T10 laminectomy only without SCI. The 'intact controls' (n = 8) did not receive any surgical procedures. A summary of the animal cohorts and tissue samples obtained is provided in Table 1 .
Peptide treatment
Peptide5 was designed to mimic a portion of the extracellular loop 2 of Connexin43 as described previously (O'Carroll et al. 2008) . All peptides were solid phase synthesised, using chemistries on a Protein technologies, Symphony instrument, purified by high-performance liquid chromatography and the structure confirmed by mass spectrometry analysis. The dose of peptides used was chosen to match previous studies (Danesh-Meyer et al. 2012; Mao et al. 2017) , to give an initial blood concentration of 100 μM. In the first cohort, a single dose of fluorescein isothiocyanate (FITC)-conjugated Peptide5 (sequence FITC-A-VDCFLSRPTEKT, Auspep; 3.5 mg in 0.5 mL saline, equivalent to 10 mg/kg of Peptide5) was injected intraperitoneally to the SCI (n = 8) and intact control (n = 8) rats immediately after surgery. In the second cohort, three doses of Peptide5 (sequence VDCFLSRPTEKT, Mimotopes) or scrambled peptide (SP) (sequence RFKPSLCTTDEV, Mimotopes) were delivered intraperitoneally to SCI (n = 22) and sham (n = 16) rats at 0 h (10 mg/kg in 0.5 mL saline), 2 h (5 mg/kg in 0.5 mL saline), and 4 h (2.5 mg/kg in 0.5 mL saline) following surgery. A single dose of vehicle control (0.5 mL saline) was delivered intraperitoneally to sham animals (n = 3).
Post-operative care
Post-operative animals were housed individually and given subcutaneous antibiotics (cephalothin sodium, 0.33 mg/kg), analgesics (buprenorphine hydrochloride, 0.03 mg/kg), and supplementary fluid (Hartman replacement solution, 3.8 mL) twice daily. Bladders were expressed manually twice daily.
Euthanasia and tissue preparation
The FITC-Peptide5 treated animals were euthanized with sodium pentobarbital (100 mg/kg, i.p.) and perfused intracardially with 200 mL of heparinized saline at 2 h (n = 8) and 4 h (n = 8) after surgery. Approximately 10 mm of spinal cord centred at T10 and cervical enlargement as well as the major organs (brain, heart, lung, liver, spleen and kidney) were dissected for generating fresh frozen sections of 15 μm onto Matsunami Platinum PLC-14 glass slides, using a cryostat (Leica, CM1950). Slides were rehydrated in water for 5 min and cover-slipped in fluorescent mounting medium (Dako).
The Peptide5 or SP treated animals were euthanized at 8 h (n = 6) and 24 h (n = 35) post-injury with sodium pentobarbital (100 mg/kg, i.p.). Cardiopuncture was then performed to collect 5 mL of blood, and the plasma was extracted. Intracardial perfusion using heparinized saline and 4% paraformaldehyde was performed. Approximately 20 mm of spinal cord centred at T10 were dissected and post-fixed in 4% paraformaldehyde overnight and then stored in 30% sucrose, while hearts and lungs were removed and post-fixed in 10% formalin. Spinal cords were sectioned horizontally in a cryostat (Leica, CM1950). Sections were mounted in a series of 10 so that each section on a slide was at 150 μm intervals. Approximately 5 × 5 × 3 mm 3 of heart and lung specimens along with a representative lumbar spinal cord specimen (SCI with Peptide5 treatment at 8 h post-injury) were processed for paraffin embedding and sections were cut at 5 μm. Mayer's haematoxylin and eosin (H&E) staining was performed to assess tissue morphology. 
Immunohistochemistry
Slides were rehydrated in xylene, decreasingly graded ethanol and phosphate buffered saline with Triton X-100 at pH 7.4 (PBST), and incubated in 5% normal goat serum (NGS) in PBST for 30 min. Primary antibodies were diluted in phosphate buffer with 2% NGS (PBG) and incubated overnight at 4 °C. For the frozen sections of T10 spinal cord, primary antibodies used were rabbit anti-Connexin30 (1:250, Thermo Fisher), rabbit anti-Connexin36 (1:250, Thermo Fisher) and rabbit anti-Connexin47 (1:250, Thermo Fisher). For the paraffin sections of heart and lung, primary antibodies used were rabbit anti-Connexin43 (1:2000, Sigma-Aldrich) and rabbit-phosphorylated Connexin43-Ser368 (1:100, Santa Cruz). The phosphorylation of Connexin43 at Ser368 was used to recognise the closed state of Connexin43 hemichannels (Faigle et al. 2008; Lampe et al. 2000; O'Carroll et al. 2013 in PBG for 2 h at room temperature. Primary antibodies were omitted from negative controls. All slides were coverslipped in fluorescent mounting medium (Dako). Representative paraffin sections of lumbar spinal cord were used to demonstrate the co-localisation of Connexin30 on astrocytes, Connexin36 on neurons, Connexin43 on astrocytes, and Connexin47 on oligodendrocytes. Slides were rehydrated in xylene, decreasingly graded ethanol and PBST. Heat-induced antigen retrieval was performed in citrate buffer (10 mM citric acid, pH 6.0) for 10 min in a pressure cooker for Connexin36/neuronal nuclei (NeuN) staining. All sections were incubated in blocking agents for 30 min at room temperature (5% NGS in PBST for Connexin30/glial fibrillary acidic protein (GFAP), Connexin43/GFAP and Connexin47/oligodendrocyte specific protein (OSP); 5% skim milk for Connexin36/ NeuN). The primary antibodies of rabbit anti-Connexin30 (1:250, Thermo Fisher), rabbit anti-Connexin36 (1:250, Thermo Fisher), rabbit anti-Connexin43 (1:2000, SigmaAldrich) or rabbit anti-Connexin47 (1:250, Thermo Fisher) were diluted in PBG and incubated overnight at 4 °C. After washing in PBST three times, the slides were incubated with secondary goat anti-rabbit Alexa Fluor 488 or 568 antibody (1:200, Thermo Fisher) in PBG for 2 h at room temperature. After washing in PBST five times, the slides were incubated with primary antibodies of rabbit anti-GFAP (1:1000, Dako), mouse anti-NeuN (1:1000, Millipore) or rabbit anti-OSP (1:3000, Abcam) in PBG overnight at 4 °C. Following washing in PBST three times, the slides were incubated with the secondary goat antirabbit Alexa Fluor 488 or 568 antibody (1:200, Thermo Fisher) in PBG for 2 h at room temperature. Slides were then washed with PBST and counterstained by Hoechst (1:5000, Thermo Fisher) for 10 min. Primary antibodies were omitted from negative controls. All slides were cover-slipped in fluorescent mounting medium (Dako).
Imaging and quantification
Imaging was conducted using an Olympus BX-51 light microscope with an Olympus U-RFL-T fluorescence burner and appropriate filters. The black balance was adjusted using the negative control sections to normalise the mean grey scale value (GSV). Frozen spinal cord sections were aligned using the central canal as an anatomical landmark (midline) for immunohistochemistry analysis. Images were taken adjacent to the lesion and at both 3.5 and 7 mm distal to the lesion centre in both rostral and caudal directions. Image analysis was conducted using ImageJ software (National Institutes of Health, version 2X). Analysis of fluorescent immunohistochemistry was undertaken by measuring the total fluorescent intensity per image, mean GSV, in 20× images. High power images (100×) were taken for the double labelling of connexins and neural markers for visualising the distribution.
Multiplex assay
The plasma samples obtained from the 24-h post-injury groups in Cohort II (n = 8 per group) were used for a multiplex assay to compare cytokines, chemokines and growth factors, as per the manufacturer's protocol (Bio-Rad, Bio-Plex Pro™ Rat Cytokine 23-Plex Assay #L8001V11S5). Briefly, plasma samples were diluted 1:4 and analysed following the manufacturer's instructions. The plates were pre-wetted with wash buffer (Bio-Rad) and loaded with 1× beads (Bio-Rad). The wells were rinsed by wash buffer (Bio-Rad) and then loaded with blank, standards, or samples for 1-h incubation. Following washing three times, the detection antibodies were added for 30-min incubation. The plates were washed and incubated in streptavidin-phycoerythrin for 10 min. After washing, the analytes were resuspended with assay buffer (Bio-Rad) for 30 s. The plates were read using the Bio-Plex reader (Bio-Rad), and results were converted to a pg/mL concentration for all of the cytokines tested.
Statistical analysis
All data were expressed as mean ± standard error of the mean (SEM). Unpaired t test or one-way analysis of variance (ANOVA) with a Bonferroni post hoc test was used to determine significant differences (PRISM, Version 6.0e, GraphPad). Differences were considered statistically significant at p < 0.05. There were no significant differences 1 3 d Immunohistochemistry analysis showed no statistically significant differences in the level of Connexin43 immunoreactivity in the heart tissue between groups. e Immunohistochemistry analysis showed no statistically significant differences in the level of phosphorylated Connexin43 immunoreactivity in the heart tissue between groups. GSV greyscale value, P5 Peptide5, p-Connexin43 phosphorylated Connexin43, SCI spinal cord injury, SP control scrambled peptide (colour figure online) between rostral and caudal measurements in mean GSV using the paired t-test and, therefore, the mean of rostral and caudal measurements for each sample was used for further analysis.
Results
Distribution of Peptide5 in vivo
All surgical procedures and intraperitoneal injections of FITC-Peptide5 were conducted without incident. None of the rats showed any indication of complications from the SCI surgery or intraperitoneal injection. FITC-Peptide5 was visualised as green fluorescence in the frozen sections (Fig. 1) . There was no evidence of FITC-Peptide5 distribution in the cervical enlargement of spinal cord, brain, heart and liver tissue in either intact or SCI animals. FITCPeptide5 was found in lung, spleen and kidney tissue in both control and SCI animals. FITC-Peptide5 presented in the T10 segment of spinal cord in the SCI rats, but not the intact controls.
Connexin43 protein in the heart tissue
Due to the known abundance of Connexin43 protein in the heart, additional investigation was undertaken using histology to confirm that there was no obvious alteration to the cardiac tissue or connexin43 levels as a result of peptide treatment. Heart sections stained by Mayer's H&E showed figure online) the typical histological characteristics of cardiac muscle: single central nuclei, branching cell shape and muscle striation (Fig. 2a) . There were no observed differences in the histological morphology of heart tissue or the distribution of fluorescent staining between groups. Fluorescent immunohistochemistry staining demonstrated Connexin43 (Fig. 2b) and phosphorylated Connexin43 at residue Ser368 (Fig. 2c) proteins in the intercalated discs of heart tissue. The immunoreactivity levels of Connexin43 and phosphorylated Connexin43 were measured by mean GSV for statistical analysis. There were no statistically significant differences in the immunohistochemistry labelling intensity of Connexin43 (36.06 ± 9.32) between groups (Fig. 2d) . Similarly, no significant differences were found in the immunohistochemistry staining intensity of Connexin43 phosphorylation at residue Ser368 (18.86 ± 3.73) between groups using one-way ANOVA analysis (Fig. 2e ).
Connexin43 protein in the lung tissue
Due to the observation of FITC-Peptide5 in the lung sections additional investigation was undertaken using histology to confirm that there was no obvious alteration to the respiratory tissue or connexin43 levels as a result of peptide treatment. Lung sections stained by Mayer's H&E staining showed histological characteristics typical of alveolar tissue: alveolar wall lined by type 1 pneumocytes (squamous epithelial cells) and type 2 pneumocytes (cuboidal epithelial cells), as well as alveolar macrophages found in the alveolar ducts and sacs (Fig. 3a) . In particular, the thickness of the alveolar wall and the number of erythrocytes were significantly increased in both spinal cord injured and sham rats compared with that expected in intact rats (Abdelaziz et al. 2016; Gauter-Fleckenstein et al. 2014; van den Brule et al. 2014) . The alveolar wall was partially incomplete in all lung samples. However, there were no observed differences in the histological morphology of lung tissue between groups. Fluorescent immunohistochemistry indicated that there was no Connexin43 protein located in lung tissue, so no further fluorescent immunohistochemistry staining of Connexin43 phosphorylation at residue Ser368 was conducted. The FITC-Peptide5 observed in the lungs is thought to be due to an artefact of cardiac perfusion.
Major connexin proteins in the spinal cord tissue
Immunohistochemical co-labelling for Connexin43 and GFAP, Connexin30 and GFAP, Connexin36 and NeuN, as well as Connexin47 and OSP was performed to determine the location of Connexin43, 30, 36 and 47 in the rat spinal cord (Fig. 4) . Connexin30 and 43 expression was found to be associated with astrocytes and their processes labelled for GFAP. Neuronal cells labelled by NeuN co-expressed Connexin36 protein in the spinal cord. Connexin47 expression was found to be associated with oligodendrocytes and their processes labelled by OSP. We previously demonstrated that SCI causes an upregulation of Connexin43, which is decreased by treatment with Peptide5 (Mao et al. 2017) . We, therefore, further analysed expression levels of Connexin30, 36 and 47 in the T10 frozen spinal cord sections at 8 and 24 h following injury.
Protein levels of Connexin30, 36 and 47 were measured by mean GSV of immunohistochemistry labelling intensity in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and the epicentre of the lesion. At all anatomical locations, there were no statistically significant differences in Connexin30 protein levels between groups in both grey (7 mm 31.28 ± 3.14, 3.5 mm 30.67 ± 3.08, epicentre 35.38 ± 4.27) and white matter (7 mm 17.19 ± 2.00, 3.5 mm 17.50 ± 2.43, epicentre 17.35 ± 2.69) (Fig. 5) . The expression levels of Connexin36 were also not significantly different between groups in either grey (7 mm 21.26 ± 1.91, 3.5 mm 21.11 ± 1.99, epicentre 21.55 ± 1.88) or white matter (7 mm 10.82 ± 1.35, 3.5 mm 11.11 ± 1.45, epicentre 11.78 ± 1.11) (Fig. 6) . Similarly, there were no statistically significant differences found in Connexin47 protein levels between groups in both grey (7 mm: 35.56 ± 1.40, 3.5 mm 35.64 ± 1.70, epicentre 35.37 ± 2.13) and white matter (7 mm 23.52 ± 1.39, 3.5 mm 23.22 ± 1.26, epicentre 22.31 ± 2.72) (Fig. 7) .
Cytokine profile in the plasma
To evaluate whether systemic delivery of Peptide5 may affect peripheral immune responses, we tested the cytokine profile in plasma samples removed from the rats at 24 h after injury. Using a multiplex assay for rat plasma samples, nine of the analytes tested showed reportable plasma values. These were IL (interleukin)-5, IL-18, chemokine (C-C motif) ligand 5 (RANTES), chemokine (C-X-C motif) ligand 1 (GROKC), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 3α (MIP-3A), erythropoietin (EPO), macrophage colonystimulating factor (M-CSF) and vascular endothelial growth factor (VEGF). Table 2 summarises the mean concentration for each of the analytes in pg/mL. No significant Fig. 5 Immunohistochemistry staining of Connexin30 in rat spinal cord at 8 and 24 h following injury. a Representative images of Connexin30 immunofluorescence (green) at the epicentre of the lesion. Scale bar 40 μm. b Immunohistochemistry analysis showed the Connexin30 protein levels in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and the epicentre of the lesion without any significant differences between groups. GSV greyscale value, P5 Peptide5, SCI spinal cord injury, SP control scrambled peptide) (colour figure online) ◂ differences were detected between groups for any of the plasma cytokine analytes using a one-way ANOVA.
Discussion
The data presented here shows that the systemic administration of Peptide5 to rats did not appear to cause any offtarget or adverse effects in either control or SCI animals. As anticipated, Peptide5 was delivered to the lesion area of the spinal cord. This is because the permeability of the blood spinal cord-barrier (BSCB) is significantly increased following traumatic SCI (Bilgen et al. 2002; Gordh et al. 2006; Popovich et al. 1996) and the capillary bed at the lesion area is compromised (Figley et al. 2014; Soubeyrand et al. 2014 ). This provides an opportunity for Peptide5 to leak from the disrupted blood vessels of the vascular system into the damaged spinal cord tissue. Under normal physiological conditions, the selective permeability of the blood brain and/or spinal cord barrier prevents small molecules (<10 kDa) from entering the central nervous system (CNS) tissue (Habgood et al. 2007; Popovich et al. 1996) . As shown in the current study, the FITC-labelled Peptide5 (<2 kDa) was not detected in the non-injured tissue of the CNS.
Peptide5 in the spinal cord tissue
Peptide5 is synthesised to mimic a sequence on the extracellular loop 2 of Connexin43 (Kim et al. 2017) . Systemic administration of Peptide5 has been shown to successfully regulate Connexin43 protein expression levels and hemichannel closure in the injured spinal cord (Mao et al. 2017 ), and we now show here that the protein (gap junction labelling) levels of Connexin 30, 36 and 47 were unaltered using immunohistochemistry. Connexin30, abundantly expressed on astrocytes, is found in astrocyte/astrocyte gap junctions (Nagy et al. 1999; Rash et al. 2001 ) and has not been reported change in the spinal cord following traumatic injury. In the current study, there was no evidence that the Connexin30 expression levels and patterns altered in response to SCI or Peptide5 treatment. Even though the expression of Connexin30 and 43 is tightly regulated by neurons (Koulakoff et al. 2008) , further studies should investigate the interaction and relationship between these two main astrocytic connexins. Connexin36 is the major connexin found in neuron/neuron gap junctions (Lee et al. 2005; Rash et al. 2000 Rash et al. , 2001 . In agreement with a previous study (Lee et al. 2005) , the current study demonstrated that Connexin36 expression surrounding the lesion in the spinal cord did not alter in response to traumatic injury, nor was it affected by Peptide5 treatment. However, Yates et al. (2008) observed a downregulation of Connexin36 protein at the lumber enlargement distal to the injury area at 7 days after a complete T10 transection in rats. The change in Connexin36 protein below the lesion level, in association with decreased electrical coupling, has been suggested to contribute to hyperreflexia and spasticity after SCI (Yates et al. 2008 (Yates et al. , 2011 . However, the effect of Peptide5 distal to the lesion was not examined specifically in the current study. Connexin47, localised to oligodendrocytes, is known to dock with Connexin43 on astrocytes in astrocyte/oligodendrocyte gap junctions (Kamasawa et al. 2005; Kleopa et al. 2004; Li et al. 2004 ). Connexin47 expression has not been reported to change following a traumatic event on the spinal cord, despite increased expression of Connexin43 on astrocytes. This may suggest that the upregulated Connexin43 following SCI contributes primarily to the gap junctions between astrocytes rather than between astrocytes and oligodendrocytes.
Peptide5 in other tissues
There was no evidence of Peptide5 entering the heart tissue, indicating that Peptide5 remains in the vascular system rather than affecting the Connexin43 hemichannels on cardiomyocytes. This was further confirmed by the immunohistochemistry studies, showing that both Connexin43 protein and phosphorylated Connexin43 protein (hemichannel closure) levels in the heart tissue did not differ between Peptide5 treatment and controls at either 8 or 24 h following SCI.
Peptide5 has been used for other applications, such as retinal ischaemia (Chen et al. 2014 (Chen et al. , 2015 Danesh-Meyer et al. 2012) , cerebral ischaemia (Davidson et al. 2012b) and in an epileptiform lesion model (Yoon et al. 2010 ), but potential off-target effects on cardiomyocytes has not been reported. Another Connexin43 mimetic peptide, Gap26 (sequence VCYDKSFPISHVR), synthesised to modulate Connexin43 hemichannels on cardiomyocytes. has been reported to protect the intact heart against ischaemia reperfusion injury ex vivo (Hawat et al. 2010 ) and the ischemic heart against myocardial infarction in vivo (Hawat et al. 2012) . Given these results, it is not likely that systemically delivered Peptide5 will cause any adverse impact on intact heart tissue.
Peptide5, via systemic delivery, is not expected to affect lung tissue in vivo since Connexin43 expression has not Fig. 6 Immunohistochemistry staining of Connexin36 in rat spinal cord at 8 and 24 h following injury. a Representative images of Connexin36 immunofluorescence (green) at the epicentre of the lesion. Scale bar 40 μm. b Immunohistochemistry analysis showed the Connexin36 protein levels in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and the epicentre of the lesion without any significant differences between groups. GSV greyscale value, P5 Peptide5, SCI spinal cord injury, SP control scrambled peptide (colour figure online) ◂ 1 3 been reported in pneumocytes (Chang et al. 2013; Ishikawa et al. 2012; Márquez-Rosado et al. 2012; Rottlaender et al. 2010) , but it maybe present in the blood vessels throughout the respiratory system (Rummery et al. 2002) . In the current study, Connexin43 was not detected in lung sections by fluorescent immunohistochemistry staining in any group, but there was FITC-P5 present in the tissue sections of SCI and Sham animals, as well as abnormal histological morphology shown by H&E staining in all groups.
FITC-labelled Peptide5 found in the spleen and kidney tissue was not unexpected. The spleen, a critically important immune organ combining both innate and adaptive immunities, is responsible for capturing and destroying pathogens and foreign bodies (Cesta 2006; Mebius and Kraal 2005) . Peptide5, as a foreign body appears to be detected by the antigen-presenting cells in the spleen, such as dendritic cells, and may be being cleared by phagocytosis (Eloranta and Alm 1999; Lopes-Carvalho and Kearney 2004; van Rooijen 1990) . However, Peptide5 could also be filtered through the glomeruli into urine, as the high permeability of the glomerular capillary wall allows the molecules smaller than albumin to pass into the filtrate (Lund et al. 2003; Sandoval et al. 2012; Venkatachalam and Rennke 1978) . Similarly, a few recent studies of tissue distribution observed the accumulation of other pharmaceutical and biological agents in the spleen and their excretion through urine (Aubert et al. 2012; Baek et al. 2012; Cho et al. 2013; Jasim et al. 2015; Liang et al. 2013) .
Systemic effects of Peptide5
While it is expected that there would be inflammatory changes, such as increase in pro-inflammatory cytokines, at the site of injury in the spinal cord tissue, the effects of SCI on circulating cytokines is less clear. We, therefore, investigated SCI and Peptide5 treatments alters systemic cytokine profile. Our results demonstrate that there was no systemic inflammatory response as a result of either the SCI or the Peptide5 treatment. This further supports that there are no off-target effects of Peptide5 that might result in wide spread inflammatory changes. We have, however, previously shown that IL-1β and TNFα are significantly up regulated in spinal cord itself after injury (O'Carroll et al. 2013 ). This does not appear to translate to significant changes in Fig. 7 Immunohistochemistry staining of Connexin47 in rat spinal cord at 8 and 24 h following injury. a Representative images of Connexin47 immunofluorescence (green) at the epicentre of the lesion. Scale bar 40 μm. b Immunohistochemistry analysis showed the Connexin47 protein levels in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and the epicentre of the lesion without any significant differences between groups. GSV greyscale value, P5 Peptide5, SCI spinal cord injury, SP control scrambled peptide (colour figure online) ◂ Table 2 Comparison of cytokines, chemokines and growth factors in rat plasma 24 h after injury There were no significant differences between groups for any of the analytes using a one-way analysis of variance EPO erythropoietin, GROKC chemokine (C-X-C motif) ligand 1, IL plasma cytokines, however, at least at the 24 h post-injury time point. Prior to clinical translation further toxicity studies will be required to determine if Peptide5 causes any subtler immunomodulatory changes. Neither sham animals treated with Peptide5 nor animals treated with the SP control showed any evidence of adverse effects in this study or in other studies using Peptide5 (Danesh-Meyer et al. 2012; Davidson et al. 2012a) . Further, there were no statistically significant differences between Peptide5 and SP-treated sham animals in previously undertaken molecular, cellular and behavioural analyses (Mao et al. 2017) . It is suggested that Peptide5 rarely travels to the uninjured tissue, nor should it act globally on gap junctions in other organs at the low concentration used in the current study. While, higher doses may prove adverse, as reported for example in a foetal model of ischaemia in sheep (Davidson et al. 2013b) , systemic effects of low dose Peptide5 have not been reported in any in vivo models when delivered locally (Chen et al. 2014 (Chen et al. , 2015 Danesh-Meyer et al. 2012; Davidson et al. 2013a Davidson et al. , b, 2014 Davidson et al. , 2015 O'Carroll et al. 2013) , or systemically (Danesh-Meyer et al. 2012; Mao et al. 2017) . Similarly, Hawat et al. (2012) did not report any systemic or adverse events after intravenous injection of another Connexin43 mimetic peptide, Gap26, into rats with myocardial infarction. Given the short timeframe of 24 h in the current study, further investigation is required to determine whether there are any the long-term effects of systemic Peptide5 treatment on the injured spinal cord and other uninjured tissues, and it will be necessary to establish a full toxicity profile for systemic Peptide5 delivery prior to human testing. Our results, however, suggest that the systemic administration of Peptide5 is unlikely to result in deleterious effects on the non-injured spinal cord, other major organs and systemic inflammatory responses, and this peptide is expected to offer a safe treatment option for traumatic SCI.
